Ji, Linong http://orcid.org/0000-0002-3262-2168
Agesen, Rikke M. http://orcid.org/0000-0002-7649-7928
Bain, Stephen C. http://orcid.org/0000-0001-8519-4964
Fu, Fangming http://orcid.org/0000-0002-0874-7526
Gabery, Sanaz http://orcid.org/0000-0002-2243-7540
Geng, Jianlin http://orcid.org/0009-0001-6844-9221
Li, Yiming http://orcid.org/0000-0002-1828-8765
Lu, Yibing
Luo, Bifen http://orcid.org/0000-0001-7166-278X
Pang, Wuyan
Tao, Yi http://orcid.org/0009-0003-6453-5354
,
Funding for this research was provided by:
Novo Nordisk A/S
Article History
Received: 5 October 2023
Accepted: 22 January 2024
First Online: 10 July 2024
Acknowledgements
: Medical writing and editorial support were provided by A. Pearson (Apollo, OPEN Health Communications, London, UK) and were funded by Novo Nordisk, in accordance with Good Publication Practice 3 (GPP3) guidelines (). The authors thank the participants, the investigators, all trial site staff and all Novo Nordisk A/S employees involved in the trial. The authors also thank W. Liu of Novo Nordisk (China) Pharmaceuticals Co. for her role in reviewing this manuscript.
: Data will be shared with bona fide researchers submitting a research proposal approved by the independent review board. Information on requesting access to datasets can be found at . Data will be made available after research completion and approval of the product and product use in the European Union and the USA. Individual participant data will be shared in data sets in a de-identified/anonymised format.
: This trial was funded by Novo Nordisk A/S, Søborg, Denmark. The study sponsor was involved in study design, data collection, analysis and interpretation and the writing of this report.
: LJ reports receiving consulting and lecture fees from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Medtronic, Merck, MSD, Novo Nordisk, Roche and Sanofi-Aventis. RMA and SG are employees and shareholders of Novo Nordisk A/S. SCB has received honoraria, teaching and research sponsorship/grants from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, MSD, Novo Nordisk, Pfizer, Sanofi and Takeda. BL and YT are employees of Novo Nordisk (China) Pharmaceuticals Co. All other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.
: All authors made substantial contributions to the conception and design of the trial, acquisition of data and/or the analysis and interpretation of data. All authors had access to the study data, critically reviewed the manuscript and approved the final version to be published. LJ, RMA, SG, BL and YT are guarantors of this work and, as such, have full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.